Compare DCTH & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | BNTC |
|---|---|---|
| Founded | 1988 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.1M | 371.0M |
| IPO Year | 2015 | 2020 |
| Metric | DCTH | BNTC |
|---|---|---|
| Price | $9.34 | $12.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $22.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 506.6K | 167.2K |
| Earning Date | 05-25-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | 80.94 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.20 | N/A |
| Revenue Next Year | $29.54 | N/A |
| P/E Ratio | $129.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $9.85 |
| 52 Week High | $18.23 | $17.15 |
| Indicator | DCTH | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 59.09 |
| Support Level | $8.90 | $11.30 |
| Resistance Level | $10.39 | $12.75 |
| Average True Range (ATR) | 0.42 | 0.74 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 51.30 | 65.83 |
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.